Vol 22, No 4 (2019)

It was supposed that endometriosis development is associated with autoimmune disorders, but the character of B-lymphocytes functioning during this gynecological disease practically is not studied. The aim of our work was to elucidate the character of the peripheral and peritoneal B-cells differentiation in patients with endometriosis and infertility. 59 women, who underwent surgical treatment of infertility in gynecological clinic, were carried out into investigation. I–II stages of endometriosis were diagnosed in 35 women and III–IV stages – in 24 women. 31 women, who underwent surgical sterilization, formed a control group. Peripheral blood and peritoneal fluid were used as the material for investigation. Peripheral and peritoneal B-lymphocytes phenotype was estimated by multicolor flow cytometry. It was found that during endometriosis at the systemic and local level the content of plasma cells, unswitched CD19⁺IgD⁺CD27– naïve B-lymphocytes was increased and the level of switched CD19⁺IgD^–CD27⁺ memory B-cells was diminished. In peritoneal fluid of women with endometriosis the amount of unswitched CD19⁺IgD⁺CD27⁺ memory B-cells was also decreased. In healthy women the population of peritoneal B-lymphocytes differed from peripheral B-lymphocytes by higher content of unswitched CD19+IgD+CD27+ memory B-cells and lower level of naïve B-lymphocytes. In women with endometriosis at the local level the amount of unswitched CD19⁺IgD⁺CD27^– naïve B-lymphocytes and switched CD19⁺IgD^–CD27⁺ memory B-cells was lower and levels of CD27^–IgD^– and CD27⁺IgD⁺ memory Bcells were higher than that in the blood. Likely, the noted elevation of autoantibodies production during endometriosis may be due to increased levels of peripheral and peritoneal naïve B-lymphocytes and diminished amount of peritoneal unswitched memory B-cells, participated in the regulation of the autoantobodies production. 

Polyoxidonium increases the immunogenicity and protection of the live plague vaccine, but the cellular mechanisms underlying its immunomodulating effect are not well understood. In present study, the blood granulocyte phagocytic activity (PA) of anti-plague vaccinated and not vaccinated BALB / c mice in relation to Yersinia pestis, Escherichia coli and Staphylococcus aureus was investigated using flow cytometry. The results of the phagocytic reaction were taken into account in the microvolumes of whole blood on days 3, 7 and 21 of immunogenesis. Spontaneous and CoA-induced cytokine production (IFN-γ and IL-10) was evaluated in the blood by an ELISA method. In one of the groups of animals, anti-plague vaccination was carried out against the background of immunomodulation with a polyoxidonium. It was established that in intact mice the blood granulocyte PA in relation to Y. pestis cells is twice as low as in experiments with E. coli and S. aureus cells. Anti-plague vaccination specifically activated in vitro the blood granulocyte absorptive capacity only in relation to plague microbes. Against the background of the polyoxidonium immunomodulating effect, PA increased in experiments with Y. pestis cells already on the 3rd day of immunogenesis, which is consistent with the known ability of this immunomodulator to stimulate earlier antibody genesis during anti-plague vaccination. In addition, an increase in phagocytic index values correlated with an increase in spontaneous and induced cytokine production in blood samples of animals vaccinated against the plague. The data obtained reflect the dependence of blood leukocyte PA from the pathogen type, specific antibodies and cytokines. They indicate that the polyoxidonium ability to increase the live plague vaccine protectivity may be associated with the activation of leukocyte PA to plague microbes.

Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory efficacy of the drug.